Drug industry called for more R&D tax cut.

The Korea Pharmaceutical Manufacturers Association (KPMA: chairman Kim Jeong-soo) proposed to the government authorities including the MOFE, MOHW, MOST and MOIE on April 27 that a tax privilege as prescribed in the special tax privilege law should extend to the pharmaceutical R&D.

The KPMA claimed that the government R&D encouragement policies should focus on more tax benefits extending to t...